FY2025 EPS Estimates for Neurocrine Biosciences, Inc. Lifted by Analyst (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Analysts at William Blair boosted their FY2025 earnings per share (EPS) estimates for shares of Neurocrine Biosciences in a research note issued to investors on Wednesday, April 17th. William Blair analyst M. Minter now forecasts that the company will post earnings per share of $6.58 for the year, up from their previous forecast of $5.28. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.84 per share.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.13 by $0.31. The business had revenue of $515.20 million during the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. Neurocrine Biosciences's revenue was up 25.0% on a year-over-year basis. During the same quarter last year, the company earned $0.88 EPS.

NBIX has been the subject of several other research reports. Wells Fargo & Company raised their target price on Neurocrine Biosciences from $127.00 to $140.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 8th. Mizuho lifted their price objective on Neurocrine Biosciences from $116.00 to $140.00 and gave the company a "neutral" rating in a research report on Thursday, February 8th. Barclays lifted their price objective on Neurocrine Biosciences from $145.00 to $150.00 and gave the company an "overweight" rating in a research report on Tuesday, January 23rd. StockNews.com upgraded Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Thursday, February 8th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, April 10th. Six investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $139.67.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock traded down $0.54 during midday trading on Friday, hitting $132.00. 556,052 shares of the company were exchanged, compared to its average volume of 843,646. The firm has a market cap of $13.14 billion, a P/E ratio of 54.55 and a beta of 0.25. Neurocrine Biosciences has a 52 week low of $89.04 and a 52 week high of $148.37. The firm has a 50 day simple moving average of $136.15 and a 200-day simple moving average of $126.99.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NBIX. Rice Hall James & Associates LLC boosted its position in shares of Neurocrine Biosciences by 195.5% during the first quarter. Rice Hall James & Associates LLC now owns 206,755 shares of the company's stock worth $19,383,000 after buying an additional 136,782 shares during the period. HighTower Advisors LLC boosted its position in shares of Neurocrine Biosciences by 48.8% during the first quarter. HighTower Advisors LLC now owns 5,745 shares of the company's stock worth $544,000 after buying an additional 1,883 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Neurocrine Biosciences by 27.7% during the first quarter. PNC Financial Services Group Inc. now owns 3,150 shares of the company's stock worth $296,000 after buying an additional 684 shares during the period. Acadian Asset Management LLC acquired a new position in shares of Neurocrine Biosciences during the first quarter worth about $27,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Neurocrine Biosciences by 39.1% during the first quarter. Dimensional Fund Advisors LP now owns 417,604 shares of the company's stock worth $39,148,000 after buying an additional 117,422 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Ingrid Delaet sold 200 shares of Neurocrine Biosciences stock in a transaction on Monday, March 11th. The stock was sold at an average price of $140.00, for a total transaction of $28,000.00. Following the completion of the sale, the insider now directly owns 7,507 shares of the company's stock, valued at $1,050,980. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Neurocrine Biosciences news, insider Ingrid Delaet sold 200 shares of the business's stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $140.00, for a total value of $28,000.00. Following the completion of the transaction, the insider now directly owns 7,507 shares of the company's stock, valued at $1,050,980. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Eric Benevich sold 19,818 shares of the business's stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $133.36, for a total value of $2,642,928.48. Following the completion of the transaction, the insider now directly owns 40,778 shares of the company's stock, valued at $5,438,154.08. The disclosure for this sale can be found here. Insiders sold a total of 196,994 shares of company stock valued at $27,205,009 over the last three months. Company insiders own 4.40% of the company's stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.